Decaquinon Description

Each tablet also contains the following excipients: FD&C Yellow No. 6 (sunset yellow FCF), carnauba wax, hydrated silicon dioxide, microcrystalline cellulose, titanium oxide, stearic acid, calcium stearate, talc, precipitated calcium carbonate, corn starch, lactose hydrate, white shellac, hydroxypropylcellulose, pullulan, povidone and macrogol 6000.
Ubidecarenone is (2E, 6E, 10E, 14E, 18E, 22E, 26E, 30E, 34E, 38E)-2-(3, 7, 11, 15, 19, 23, 27, 31, 35, 39-Decamethyltetraconta-2, 6, 10, 14, 18, 22, 26, 30, 34, 38-decaen-1-yl)-5, 6-dimethoxy-3-methyl-1, 4-benzoquinone.
Molecular Formula: C₅₉H₉₀O₄. Molecular Weight: 863.34.
Ubidecarenone occurs as a yellow to orange, crystalline powder. It is odorless and tasteless. It is freely soluble in diethylether, very slightly soluble in ethanol (99.5) and practically insoluble in water. It is gradually decomposed by light and darkens.
Melting Point: Approximately 48°C.
Ubidecarenone (Coenzyme Q₁₀, Ubiquinone 50), the active ingredient of Decaquinon, was 1st isolated in 1957 as fat-soluble crystals from the bovine heart muscle. Later, Cooly and Folkers and their colleagues demonstrated that ubidecarenone activity is low in the myocardium of patients with heart disease. Ubidecarenone (CoQ₁₀), administered orally, is absorbed via the lymphatic system and is incorporated into intracellular mitochondria. It has now been confirmed that CoQ₁₀ acts directly on ischemic myocardium and improves the efficiency of oxygen utilization. These actions of CoQ₁₀ enable the heart muscle to maintain high levels of energy-producing functions, even under ischemic conditions, thus reducing ischemia-induced myocardial damage. Clinically, the effect of CoQ₁₀ on myocardial disorders was studied observing electrocardiograms at rest and with exercise loading, and it was confirmed that CoQ₁₀ administration normalized the depressed cardiac function. Furthermore, double-blind controlled clinical trials have demonstrated the efficacy of Decaquinon in improving the symptoms of congestive heart failure associated with decreased left ventricular function due to chronically ischemic heart or hypertensive heart disease.